Rigel Pharmaceuticals (RIGL) to Release Earnings on Tuesday

Rigel Pharmaceuticals (NASDAQ:RIGL) is set to issue its quarterly earnings data after the market closes on Tuesday, May 7th. Analysts expect the company to announce earnings of ($0.03) per share for the quarter.

Rigel Pharmaceuticals Stock Up 3.8 %

NASDAQ:RIGL traded up $0.04 during mid-day trading on Wednesday, hitting $1.09. 149,119 shares of the company traded hands, compared to its average volume of 1,321,587. The stock’s fifty day moving average price is $1.33 and its 200-day moving average price is $1.20. Rigel Pharmaceuticals has a one year low of $0.71 and a one year high of $1.96. The firm has a market cap of $191.19 million, a price-to-earnings ratio of -7.27 and a beta of 0.95.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Cantor Fitzgerald upped their price objective on Rigel Pharmaceuticals from $2.00 to $3.00 and gave the stock a “neutral” rating in a research note on Wednesday, March 6th. Citigroup upped their price objective on Rigel Pharmaceuticals from $3.00 to $4.00 and gave the stock a “buy” rating in a research note on Thursday, March 7th. StockNews.com lowered Rigel Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, April 4th. B. Riley reaffirmed a “neutral” rating and issued a $1.25 price objective on shares of Rigel Pharmaceuticals in a research note on Wednesday, March 6th. Finally, HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of Rigel Pharmaceuticals in a research note on Wednesday, March 6th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $5.81.

Rigel Pharmaceuticals Company Profile

Rigel Pharmaceuticals, Inc, a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.